Study on ampicillin and ceftriaxone for heart valve infection
Part of Heart & circulation clinical trials.
This trial tests a combination of two antibiotics (ampicillin and ceftriaxone) to treat a heart valve infection caused by Enterococcus faecalis bacteria. It aims to see how well the medicine works and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a heart valve infection (endocarditis) caused by Enterococcus faecalis bacteria, either confirmed or suspected.
- You must be willing and able to sign a consent form agreeing to take part.
- You cannot be allergic to penicillin or cephalosporin antibiotics.
- You cannot be pregnant or breastfeeding.
- You cannot have an infection with other bacteria besides Enterococcus faecalis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares taking antibiotics by mouth versus receiving antibiotics through a vein (outpatient IV) for an infection of the heart valve. It’s designed to see whether the oral option can work as well and safely, especially after initial treatment and surgery if needed.
This trial tests if the antibiotic dalbavancin can effectively treat a certain type of serious heart valve infection (endocarditis) caused by specific bacteria. You may be eligible if you have this infection in your left-sided heart valves and are at least 18 years old.
This trial measures how your body handles certain intravenous antibiotics used for endocarditis, an infection of the heart valves. It may help doctors understand the best antibiotic dosing for people with valve infections.
This trial tests whether a treatment without rifampin works as well as one with rifampin for a type of heart valve infection caused by staph bacteria. It aims to find a simpler and safer option for patients with an infected artificial heart valve.
This Phase 4 trial studies treatment for an infection of the heart valves caused by certain enterococcus bacteria. It may help improve how these infections are treated in real-world care.
This trial tests if adding bacteriophages (viruses that kill bacteria) to standard antibiotic treatment can help people with a serious heart valve infection called infective endocarditis. It may offer a new way to fight the infection.
Hear when a new Endocarditis, Infective trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.